Trump announces 0% generic drug tariff for two years, then steep hike

United States President Donald Trump announced on Tuesday that generic drugs will be exempt from US tariffs for the next two years, after which they will face a 100% tariff, eventually rising to 200%. The phased plan is the latest move in the administration's push to bring pharmaceutical manufacturing back to American soil.

The announcement, made in a statement from the White House, did not specify exact dates or the legal mechanism for implementing the steep increases. Officials have not yet confirmed whether the plan requires legislative approval or can be enacted through executive action.

Two-Year Grace Period

During the first two years, generic drugs imported into the United States will face zero tariffs. This window is intended to give pharmaceutical companies time to adjust to the coming changes.

Industry analysts say the grace period could trigger a short-term surge in Indian generic drug exports to the US, as buyers stockpile supplies before the tariffs kick in. India is the world's largest supplier of generic medicines, with exports to the US valued at over $8 billion annually.

Escalation to 100% and 200%

After the two-year period, the tariff will jump to 100%. The statement indicated that the rate would later rise to 200%, though it did not provide a timeline for the second increase.

The Trump administration has framed the policy as a way to reduce American dependence on foreign-made medicines, particularly from India and China. Similar tariff threats have been used in the past to pressure countries into trade negotiations.

Impact on Indian Pharma Sector

Indian pharmaceutical companies, including major exporters like Sun Pharma, Dr. Reddy's, and Cipla, are likely to be among the most affected. The sector generates a significant share of its revenue from the US market.

Shares of Indian pharma companies saw mixed reactions in early trading on Wednesday. The Nifty Pharma index dipped 0.6% in morning trade as investors digested the long-term implications. Analysts warned that a 200% tariff would effectively price out most Indian generics from the US market unless companies set up manufacturing facilities in America.

Some Indian firms have already begun establishing US-based production units in anticipation of such moves. The two-year exemption may accelerate those plans, but building new factories typically takes three to five years.

Unanswered Questions

It remains unclear whether the tariff plan covers all generic drugs or includes exemptions for critical medicines. The White House has not released a detailed list of products that would be affected.

Trade experts also noted that the plan could violate World Trade Organization rules. India may challenge the tariffs at the WTO if they are implemented, though such disputes can take years to resolve.

For now, the Indian pharmaceutical industry is watching closely. The next two years will be critical for companies deciding whether to invest in US manufacturing or seek alternative markets in Europe, Africa, and Southeast Asia.